Last reviewed · How we verify
NCT03575117
Views on Cancer Prevention and Daily Lifestyle
NA trial testing Common-Sense Model (CSM) Be Well in Colorectal Cancer in 84 participants. Completed in 31 December 2019.
15 August 2018
Quick facts
| Lead sponsor | University of California, Merced |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 84 |
| Start date | 1 May 2018 |
| Primary completion | 15 August 2018 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Common-Sense Model (CSM) Be Well
- ACS usual messages
- NCI HealthyYouTXT--Get Active (HYT--GA)
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Sedentary Lifestyle — all drugs for Sedentary Lifestyle →
Sponsor
University of California, Merced
Who can join
Adults 18 to 65, any sex, with Colorectal Cancer or Sedentary Lifestyle. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to assess how a theoretically guided mHealth communication informed by evidence of thoughts and affect about colorectal cancer can enhance how an existing mHealth (cell/mobile based text messaging health promotion) intervention increased physical activity in healthy adults.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03575117
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other University of California, Merced trials
Trials by the same sponsor.
- NCT04710108 — Testing Message Modality of Culturally Appropriate Nutrition Communication for Mexican American Women · NA · completed
- NCT04352530 — Culturally Appropriate Nutrition Communication for Mexican American Women · NA · completed
- NCT03652168 — Stress Free UC Merced: The Effect of 8 Weeks of Mindfulness App Headspace on Stress in a Sample of University Employees · Phase 3 · unknown
- NCT03566706 — Parents' View About Discussing Health Behaviors · NA · completed
- NCT03184948 — Understanding Neonatal Jaundice in Rwanda · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03575117 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Merced
- Last refreshed: 3 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03575117.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing